Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First‐Line Ibrutinib–Venetoclax
European Journal of Haematology · 2026-12 · 117 (6) · 1612-1621
DOI: 10.1111/ejh.70300 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Haematology, online erschienen am 27.08.2026. Verfasst von Liron Hofstetter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Centre, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols, Heart Diseases. Die Arbeit nennt 36 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Fixed‐duration combination of ibrutinib and venetoclax (IV) has emerged as a highly effective first‐line treatment for chronic lymphocytic leukemia (CLL). However, the cardiac safety profile of this regimen has not been comprehensively characterized. We conducted a systematic review and meta‐analysis to evaluate the incidence and relative risk of cardiac adverse events associated with frontline IV‐based therapy.
Methods
PubMed, Embase, and major hematology conference proceedings (2014–2025) were searched for prospective studies evaluating first‐line IV‐based regimens in CLL/SLL. Two analyses were performed: (1) pooled incidence of cardiac events across prospective trials and (2) comparative meta‐analysis of randomized controlled trials (RCTs) comparing IV‐based therapy with chemoimmunotherapy (CIT). The primary outcome was summed cardio‐vascular events (SCE). Secondary outcomes included atrial fibrillation/flutter (AF), hypertension (HTN), ventricular arrhythmias, and cardiac mortality.
Results
Fourteen publications comprising 1522 patients were included in the pooled analysis, and four RCTs were included in the comparative analysis. The pooled incidence of SCE was 18.0% (95% CI 12.8–23.9), while grade ≥ 3 SCE occurred in 6.6% (95% CI 4.6–8.8). AF/flutter occurred in 10.8% (95% CI 8.6–13.3), with grade ≥ 3 AF in 3.6% (95% CI 2.6–4.9). HTN was reported in 19.0% (95% CI 12.5–26.8), with grade ≥ 3 HTN in 8.3% (95% CI 5.6–11.4). Ventricular arrhythmias/cardiac arrest and cardiac mortality were uncommon, occurring in 0.78% and 0.89% of patients, respectively. Compared with CIT, IV‐based therapy was associated with significantly higher risks of SCE (RR 3.61, 95% CI 2.32–5.62), grade ≥ 3 SCE (RR 6.86, 95% CI 3.05–15.43), AF (RR 5.50, 95% CI 2.68–10.10), grade ≥ 3 AF (RR 9.82, 95% CI 2.69–35.84), HTN (RR 3.73, 95% CI 2.14–6.50), and grade ≥ 3 HTN (RR 4.91, 95% CI 2.06–11.67).
Conclusions
Frontline IV‐based therapy is associated with a clinically meaningful increase in cardiac toxicity, particularly AF and HTN, compared with CIT. Nevertheless, ventricular arrhythmias and cardiac mortality remain rare. Careful cardiovascular risk assessment and monitoring should accompany the use of IV‐based regimens in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Centre, Petah Tikva, Israel.
- The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Internal Medicine Department A, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel.
- Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel.
- Department of Cardiology, Cardio Oncology Service, Rabin Medical Centre, Petah-Tikva, Israel.
- Institute of Hematology, Meir Medical Centre, Kfar-Saba, Israel.
ORCID-Profile: Liron Hofstetter, Shira Buchrits, Adi Sherban, Neta Sternbach, Pia Raanani, Anat Gafter-Gvili, Gilad Itchaki
Zitieren
APA
Hofstetter, L., Buchrits, S., Sherban, A., Sternbach, N., Raanani, P., Zadok, O. I. B., Gafter-Gvili, A., & Itchaki, G. (2026). Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First‐Line Ibrutinib–Venetoclax. European Journal of Haematology, 117(6), 1612-1621. https://doi.org/10.1111/ejh.70300
Vancouver
Hofstetter L, Buchrits S, Sherban A, Sternbach N, Raanani P, Zadok OIB, et al. Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First‐Line Ibrutinib–Venetoclax. European Journal of Haematology. 2026;117(6):1612-1621. doi:10.1111/ejh.70300
BibTeX
@article{Hofstetter2026,
author = {Hofstetter, Liron and Buchrits, Shira and Sherban, Adi and Sternbach, Neta and Raanani, Pia and Zadok, Osnat Itzhaki Ben and Gafter-Gvili, Anat and Itchaki, Gilad},
title = {Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First‐Line Ibrutinib–Venetoclax},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {6},
pages = {1612--1621},
doi = {10.1111/ejh.70300}
}
EUVIMED